Immunotech Laboratories Inc. Corporate Update
Post# of 29744
Posted On: 01/10/2014 11:07:05 PM
Immunotech Laboratories Inc. Corporate Update
MONROVIA, CA / ACCESSWIRE / January 10, 2014 / Immunotech Laboratories, Inc. (OTCMARKETS: IMMB) Immunotech Laboratories, Inc. today released the following company updates for Shareholders and Investors:
Immunotech Laboratories Inc. , A Nevada Corporation, (IMMB), is pleased to announce that the financials for the company have been completed and are currently being audited.
Blaine Nabors VP of Business Development today said Immunotech’s financials are now complete and now is in the hands of our Auditor, Travis Green, DKM Certified Public Accountants , in Florida, who will audit our financials for the upcoming S-1 registration statement.
As we are moving forward to becoming a fully reporting company, Immunotech Laboratories will begin posting information not only in this form, but investors will find information on our website as well as other social media outlets. So, please visit us at http://www.immunotechlab.com/ for complete information regarding our business model and steps we are taking to receive FDA approval for our process. In the filing of this S-1 registration statement, once it has become effective, we expect to receive support for our next step in the process with the FDA. World Finance Capital Holdings Inc. has informed us that along with this registration statement, it will also put together SWORD financing http://en.wikipedia.org/wiki/SWORD-financing for the larger part of our funding needs as we move through the phases of FDA approval.
About Immunotech:
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind.
Immunotech’s flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
About World Finance Capital Holdings: World Finance Capital Holdings is a diversified holdings company who assists public companies with finance through equity lines of credit and project financing.
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.
Contact
Blaine@immunotechlab.com
Source: Immunotech Laboratories Inc.
MONROVIA, CA / ACCESSWIRE / January 10, 2014 / Immunotech Laboratories, Inc. (OTCMARKETS: IMMB) Immunotech Laboratories, Inc. today released the following company updates for Shareholders and Investors:
Immunotech Laboratories Inc. , A Nevada Corporation, (IMMB), is pleased to announce that the financials for the company have been completed and are currently being audited.
Blaine Nabors VP of Business Development today said Immunotech’s financials are now complete and now is in the hands of our Auditor, Travis Green, DKM Certified Public Accountants , in Florida, who will audit our financials for the upcoming S-1 registration statement.
As we are moving forward to becoming a fully reporting company, Immunotech Laboratories will begin posting information not only in this form, but investors will find information on our website as well as other social media outlets. So, please visit us at http://www.immunotechlab.com/ for complete information regarding our business model and steps we are taking to receive FDA approval for our process. In the filing of this S-1 registration statement, once it has become effective, we expect to receive support for our next step in the process with the FDA. World Finance Capital Holdings Inc. has informed us that along with this registration statement, it will also put together SWORD financing http://en.wikipedia.org/wiki/SWORD-financing for the larger part of our funding needs as we move through the phases of FDA approval.
About Immunotech:
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind.
Immunotech’s flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
About World Finance Capital Holdings: World Finance Capital Holdings is a diversified holdings company who assists public companies with finance through equity lines of credit and project financing.
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.
Contact
Blaine@immunotechlab.com
Source: Immunotech Laboratories Inc.
(0)
(0)